Actively Recruiting
Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
Led by First Affiliated Hospital of Chengdu Medical College · Updated on 2024-01-29
196
Participants Needed
1
Research Sites
171 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To explore the relationship between perioperative blood pressure and catecholamine concentrations in adrenal venous blood and peripheral venous blood in hypertensive patients with primary aldosteronism (PA) who underwent percutaneous selective adrenal artery embolization (SAAE). In order to elucidate the related phenomena and possible mechanisms of blood pressure fluctuations caused by SAAE treatment in hypertensive patients with PA.
CONDITIONS
Official Title
Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age ≥18 years with no gender restrictions.
- Adherence to the "Primary Aldosteronism" Diagnosis and Treatment Guidelines, confirmed diagnosis of primary aldosteronism following rigorous drug washout, and identification as either aldosteronoma or idiopathic aldosteronism via adrenal vein blood sampling.
- Blood pressure metrics that satisfy any of the subsequent conditions: a) Clinic-recorded blood pressure ≥140/90mmHg; b) 24-hour ambulatory blood pressure monitoring results displaying average blood pressure >130/80 mmHg or daytime readings >135/85 mmHg.
- Adrenal CT scan revealing adrenal hyperplasia, nodular formations, or no significant morphological deviations.
- Hypertension history surpassing a duration of 6 months.
- Prior to screening, patients or their lawful guardians must provide a signed informed consent, sanctioned by the ethics committee.
You will not qualify if you...
- Patients diagnosed with primary hypertension or secondary hypertension attributed to other etiologies.
- Female participants who are presently pregnant, lactating, or with intentions to conceive within the forthcoming year.
- Presence of significant systemic diseases, with particular attention to hepatic and renal dysfunction.
- Pronounced allergic reaction to contrast agents.
- Any other serious systemic diseases with a life expectancy of less than 12 months.
- Participants concurrently enrolled or expressing interest to participate in other clinical trials, the outcomes of which could potentially influence the results of the current study.
- The researcher's discretion deems the subject inappropriate for inclusion in the study for any given reason.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Chengdu Medical College
Chengdu, Sichuan, China, 610500
Actively Recruiting
Research Team
P
Peijian Wang, PhD
CONTACT
S
Sen Liu, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here